iCAD (NASDAQ:ICAD) Upgraded at StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research report report published on Thursday morning.

iCAD Price Performance

ICAD opened at $1.54 on Thursday. iCAD has a 12 month low of $1.18 and a 12 month high of $2.65. The business has a 50-day moving average of $1.72 and a two-hundred day moving average of $1.54. The stock has a market capitalization of $40.87 million, a price-to-earnings ratio of -11.85 and a beta of 1.47.

Institutional Trading of iCAD

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC boosted its holdings in iCAD by 55.6% in the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after acquiring an additional 7,604 shares during the last quarter. Perritt Capital Management Inc lifted its stake in shares of iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after purchasing an additional 19,917 shares in the last quarter. Essex LLC acquired a new stake in iCAD during the 3rd quarter worth approximately $216,000. Finally, Perritt Capital Management Inc. raised its holdings in iCAD by 7.5% in the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after buying an additional 9,717 shares during the period. 24.61% of the stock is owned by hedge funds and other institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.